IRF5 and cancer: Nanoparticles formulated with mRNAs encoding the transcription factor interferon regulatory factor 5 (IRF5) and its activating kinase, inhibitor of NF-B kinase subunit-β (IKKβ), reversed the immunosuppressive TME and reprogrammed TAMs, regressing tumours in mouse cancer models (Zhang et al., 2019; Petty et al., 2021).